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Abstract  53 
Objectives: The International Collaboration for a Life Course Approach to Reproductive Health and 54 
Chronic Disease Events (InterLACE) project is a global research collaboration that aims to advance 55 
understanding of women’s reproductive health in relation to chronic disease risk by pooling 56 
individual participant data from several cohort and cross-sectional studies. The aim of this paper is to 57 
describe the characteristics of contributing studies and to present the distribution of demographic and 58 
reproductive factors and chronic disease outcomes in InterLACE.   59 
Study design: InterLACE is an individual level pooled study of 20 observational studies (12 of which 60 
are longitudinal) from ten countries. Variables were harmonized across studies to create a new and 61 
systematic synthesis of life course data.  62 
Main outcome measures: Harmonized data were derived in three domains: 1) socio-demographic 63 
and lifestyle factors, 2) female reproductive characteristics, and 3) chronic disease outcomes 64 
(cardiovascular disease (CVD) and diabetes). 65 
Results: InterLACE pooled data from 229,054 mid-aged women. Overall, 76% of the women were 66 
Caucasian, 22% Japanese, and other ethnicity (of 300 or more participants) included Hispanic/Latin 67 
American (0.2%), Chinese (0.2%), Middle Eastern (0.3%), African/black (0.5%), and Other (1.0%). 68 
The median age at baseline was 47 years (Inter-quartile range (IQR): 41-53), and that at the last 69 
follow-up was 56 years (IQR: 48-64). Regarding reproductive characteristics, half of the women 70 
(49.8%) had their first menstruation (menarche) at 12-13 years of age. The distribution of menopausal 71 
status and the prevalence of chronic disease varied considerably among studies. At baseline, most 72 
women (57%) were pre- or peri-menopausal, 20% reported a natural menopause (range 0.8-55.6%) 73 
and remaining had surgery or were taking hormones. By the end of follow-up, the prevalence of CVD 74 
and diabetes were 7.2% (range 0.9-24.6%) and 5.1% (range 1.3-13.2%), respectively.  75 
Conclusions: The scale and heterogeneity of InterLACE data provide an opportunity for 76 
strengthening evidence concerning the relationships between reproductive health through life and 77 
subsequent risks of chronic disease, including cross-cultural comparisons.   78 
Keywords: baseline characteristics; reproductive health; chronic disease; life course research; cross-79 
cultural comparison; harmonization   80 
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Highlights  81 
 InterLACE is an international collaboration of 20 observational studies across 10 countries.  82 
 Harmonized individual-level data on reproductive health and chronic disease are available 83 
from 230,000 women. 84 
 The prevalence of diabetes and cardiovascular disease among mid-aged women were 5% and 85 
7% at the end of study follow-up, respectively. 86 
 InterLACE enables a detailed review of methodologies currently used in the field of women’s 87 
health.  88 
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1. Introduction 89 
Since chronic diseases are typically characterized by long latency and complex causal pathways, the 90 
clear sex differences evident in their risks [1] highlight the need to understand the role of reproductive 91 
characteristics and sex hormones in non-communicable diseases (NCDs) across life. For instance, 92 
women with diabetes have a 3.5-fold increased risk of mortality from coronary heart disease, 93 
compared with 2-fold for men with diabetes [1]. Some aspects of female reproductive health act as 94 
markers for increased risk of NCDs in later life, in that they may signal an underlying predisposition 95 
or sub-clinical conditions [2-4]. Early menarche is associated with increased risk of type 2 diabetes 96 
mellitus (T2DM), cardiovascular disease (CVD) [5,6], and breast cancer [7]. Early menarche is also 97 
linked to poor reproductive health outcomes across life, such as irregular menstrual cycles [8], but 98 
with better bone health in later life [9,10]. Similarly, early menopause increases the risk of having 99 
chronic diseases in later life including T2DM and CVD [11,12], while the vasomotor symptoms and 100 
longer duration of menopausal transition also represent a period of increased metabolic and 101 
cardiovascular risks [13,14]. Various lifestyle, socioeconomic, and cultural factors also influence 102 
reproductive characteristics and chronic disease risk [15-17]. A more detailed understanding of the 103 
complex relationships between these modifiable factors and reproductive characteristics is needed to 104 
support targeted gender-specific preventive strategies for chronic diseases. Previous research based 105 
on individual studies has been constrained by issues such as small sample size, lack of control for 106 
comorbidities, and lack of sufficient information on the racial/ethnic and cultural diversity of the 107 
study samples. 108 
The International Collaboration for a Life Course Approach to Reproductive Health and Chronic 109 
Disease, or InterLACE, aims to advance the evidence base for women’s health policy by developing 110 
a collaborative research program that takes a comprehensive life course perspective of women’s 111 
reproductive health in relation to chronic disease risk [18]. Established in June 2012, InterLACE has 112 
pooled individual-level observational data on reproductive health and chronic disease from almost 113 
230,000 women from 20 observational studies, mostly on women’s health, across ten countries. 114 
InterLACE offers an integrated approach for a more detailed understanding of the determinants and 115 
characteristics of reproductive health across the life course in diverse populations [18]. A life course 116 
perspective emphasizes the differential effects of exposures and events at different stages of life [19], 117 
which in turn can be reflected in models that capture the different types of biological, psychological, 118 
and social mechanisms at work [20].  119 
Findings from InterLACE can therefore provide insights into causal pathways for disease aetiology 120 
[21] and have implications for the timing and targeting of preventive health interventions [22]. This 121 
will enable a more detailed description of reproductive function and ageing by quantifying the 122 
markers of reproductive health through life, such as age at menarche, parity, and age at menopause 123 
in different populations. The project will determine the extent to which these markers and overall 124 
trajectories of lifetime reproductive health are associated with future chronic disease risks such as 125 
T2DM and CVD. Through InterLACE, the relationships of lifestyle, cultural factors, and reproductive 126 
health with subsequent risk of chronic disease will be identified. Recommendations for future study 127 
designs to facilitate rigorous cross-cultural comparisons across longitudinal studies will also be 128 
presented. The aim of this paper is to present the overall demographic and reproductive characteristics 129 
and to describe the prevalence of T2DM and CVD in InterLACE.  130 
 131 
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2. Methods  132 
2.1 Study recruitment  133 
Twenty observational studies, twelve of which are longitudinal, currently provide data for 134 
InterLACE: Australian Longitudinal Study on Women’s Health (ALSWH) [23], Healthy Ageing of 135 
Women Australia (HOW) [24], Melbourne Collaborative Cohort Study (MCCS) [25], Danish Nurse 136 
Cohort Study (DNC) [26], Women's Lifestyle and Health Study (WLH) [27], Medical Research 137 
Council (MRC) National Survey of Health and Development (NSHD) [28], National Child 138 
Development Study  (NCDS) [29], English Longitudinal Study of Ageing (ELSA) [30], UK Women's 139 
Cohort Study (UKWCS) [31], Whitehall II study (WHITEHALL) [32], The Study of Women's Health 140 
Across the Nation (SWAN) [33], Seattle Midlife Women’s Health Study (SMWHS) [34], Japan 141 
Nurses’ Health Study (JNHS) [35], Japanese Midlife Women’s Health Study (JMWHS) [24], Hilo 142 
Women's Health Study (HILO) [36], San Francisco Midlife Women’s Health Study (SFMWHS) [37], 143 
and The Decision at Menopause Study (DAMES-USA [38], Lebanon [39], Spain [40], Morocco [41]). 144 
Participants in each study were recruited under Institutional Review Board protocols approved at each 145 
research centre and provided informed consent. Details of the study design, recruitment, and research 146 
aims for each study have been published elsewhere (see above for references). Brief descriptions of 147 
the 20 studies are given in Table 1, with their geographic scope shown in Figure 1.      148 
The majority of studies began between 1990 and early 2000, with the exception of NSHD (1946 149 
British Birth Cohort) and NCDS (1958 British Birth Cohort), in which participants (male and female) 150 
were recruited at birth. InterLACE used data from a sub-sample study of women’s health (n=1570) 151 
from NSHD started in 1993 (and the baseline for InterLACE), when participants were aged 47 years, 152 
with annual follow-up surveys until 2000 (age 54 years) to capture timing of menopause, menopausal 153 
symptoms and menopausal hormone therapy (MHT) use [28]. Similarly, for NCDS we used data 154 
from the women’s health survey in 2008 (n=5274) as the baseline when cohort members were aged 155 
50 years and were followed up until 2013 for disease outcome.   156 
The DNC and ELSA studies had multiple waves of recruitment. DNC first invited members of the 157 
Danish Nurses Organisation to participate in 1993, with both a follow-up and recruitment of 158 
additional nurses in 1999 [26]. ELSA commenced in 2002-03 (wave 1) with the original sample 159 
recruited from households that had earlier participated in the Health Survey for England (HSE) in 160 
1998, 1999, and 2001 (wave 0) [30]. New cohorts that were recruited from households that had 161 
participated in HSE in 2001-04 and 2006 were added to the ELSA sample at wave 3 (2006-07) and 162 
wave 4 (2008-09), respectively. The baseline years used in InterLACE for DNC and ELSA were 163 
determined according to the year in which each participant was recruited.   164 
The SWAN and SMWHS had different recruitment criteria at baseline. In SWAN, only women with 165 
at least one menstrual period in the previous three months, without surgical removal of the uterus 166 
and/or both ovaries, and without the current use of hormone therapy, were eligible. In SMWHS, only 167 
women without surgical removal of uterus or ovaries were eligible to participate.      168 
 169 
2.2 Study variables  170 
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InterLACE invited all individual studies to provide relevant data including a list of variables, survey 171 
questionnaires, data dictionaries/formats, and protocols or standard operating procedures. The data 172 
were requested from the three key domains:  173 
1. Socio-demographic and lifestyle factors: age, birth year, race/ethnicity, marital and 174 
employment status, the level of education, body mass index (BMI), smoking status, alcohol 175 
consumption, physical activity, food and vegetable intakes, the consumption of soy products were 176 
provided if available. Marital status, employment, and lifestyle variables were also available at 177 
multiple time points in some longitudinal studies and were all preserved, although only baseline 178 
data are presented here. Use of these exposure variables will vary depending on the research 179 
questions.   180 
 181 
2. Female reproductive characteristics: studies provided some or all of the following self-reported 182 
markers of reproductive health through life: age at menarche, age at first birth, number of 183 
pregnancies, parity, timing and duration of oral contraceptive pill (OCP) use, MHT use, age at 184 
natural menopause, hysterectomy/oophorectomy, menopausal status, and menopausal  symptoms 185 
(e.g. vasomotor symptoms and psychological symptoms) [20]. Time-varying reproductive 186 
variables such as hormone use, surgery history, menopausal status, and menopausal symptoms 187 
were also available at multiple surveys in the longitudinal studies.  188 
 189 
3. Chronic disease outcomes: data on CVD (stroke and heart diseases including general heart 190 
disease, heart attack, heart failure and angina) and diabetes (Type 1 and Type 2 diabetes) were 191 
collected from self-reported survey questionnaires and linkage with national registries (for DNC, 192 
WLH and SMWHS). Four studies (JMWHS, DAMES-USA, Lebanon, and Spain) did not have 193 
data available on CVD or diabetes.  194 
 195 
2.3 Data harmonization  196 
Once individual-level datasets were received, data were checked for outliers and inconsistencies, and 197 
if present, data providers were queried and the issue resolved. Harmonization rules and recoding 198 
instructions were created for each variable. When multiple studies had more detailed but similar 199 
information available, extra variables were created to encompass this alternative format and benefit 200 
from the increased granularity. In general, categorical variables were collapsed into the simplest level 201 
of detail to incorporate information from as many studies as possible. For example, education 202 
categories varied from study to study. It was categorised into ≤10 years, 11-12 years, and >12 years. 203 
Harmonized education category of less or equal to 10 years corresponds to less than high school or 204 
Certificate of Secondary Education (CSE) or General Certificate of Education Ordinary Level (GCE 205 
O-level) in the UK. Similarly, 11-12 years category corresponds to high school or GCE Advanced 206 
Level (A-level) in the UK, and >12 years corresponds to at least some college education including 207 
trade, certificate, vocational training, diploma, and university degree. 208 
Harmonization of other specific variables such as race/ethnicity and menopausal status are presented 209 
in Figures 2 and Figure 3. In detail, participants self-identified their specific race/ethnicity and/or 210 
population subgroup in ten studies from which ethnicity variable was defined. Of the remaining ten 211 
studies, ethnic groups were defined based on country of birth and language spoken at home (5 studies), 212 
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and where these were not available (DNC, JNHS, JMWHS, DAMES-Lebanon, and DAMES-213 
Morocco), the country where the study was conducted was considered as a residency variable and 214 
used as a proxy for ethnicity [42]. In total, ten ethnic groups were defined: Caucasian-Australian/New 215 
Zealander, Caucasian-European, Caucasian-North American, Hispanic/Latin American, Asian-216 
Japanese, Asian-Chinese, Asian-Other (South/Southeast Asian), Middle Eastern, African/Black, and 217 
Other (Native American, Pacific Islander, Caribbean, Hawaiian, and Mixed). We then collapsed 218 
Australian/New Zealander, European, and North American together as Caucasian, and combined 219 
Asian-Other and Other.  220 
To harmonize menopausal status at baseline, we first reviewed 14 studies that either had predefined 221 
menopausal status (pre-, peri-, or post-menopause) or reasons for the cessation of menses. Among 222 
them, those reporting current use of hormone therapy (unless natural menopause specifically reported) 223 
and hysterectomy/oophorectomy were categorised separately. As a result, we have six categories of 224 
menopausal status: hysterectomy/oophorectomy, current MHT use, current OCP use, pre-menopause, 225 
peri-menopause, and natural menopause. For all other women, where predefined menopausal status 226 
was not available, we used related variables (hysterectomy/oophorectomy, current use of hormone, 227 
menstrual period in the last 12 months, menstrual period in the last 3 months, and irregular or 228 
changeable period) using a consistent rule (Figure 3) to assign them to one of the six groups defined 229 
above. In this way, each woman was provided with consistent and harmonized data on menopausal 230 
status at baseline.  The same rules applied for the follow-up surveys. However once women had gone 231 
through natural menopause or surgery (hysterectomy/oophorectomy), their menopausal status 232 
remained throughout for any subsequent surveys. In addition to the harmonized menopausal status, 233 
more detailed information about the current and past use of MHT and OCP, hysterectomy, and 234 
unilateral/bilateral oophorectomy are available as separate variables. In this paper, we only present 235 
socio-demographic and reproductive characteristics at baseline, and show the cumulative prevalence 236 
of chronic disease outcomes over the study period. We used SAS 9.4 (SAS Institute, Inc., Cary, NC) 237 
for all data management and analysis.  238 
 239 
3. Results  240 
The InterLACE dataset pooled individual-level data from 229,054 participants. Of the twenty studies 241 
currently comprising InterLACE, nine are national cohorts from Australia, the USA, the UK, Japan, 242 
Sweden, Norway, and Denmark. The remaining state-based studies from specific cities or regions 243 
including San Francisco, Seattle, Hawaii, and Massachusetts in the USA; London, England; 244 
Melbourne and Queensland in Australia; Nagano, Japan; Beirut, Lebanon; Madrid, Spain; and Rabat, 245 
Morocco (Figure 1). Twelve studies provided longitudinal data with at least two waves of surveys 246 
and five years of follow-up, while eight studies provided only cross-sectional baseline data (Table 247 
1). For the majority of studies, women’s average age at baseline was between 40 and early 50 years 248 
with an overall median of 47 years (IQR: 41-53 years), with the exceptions of HOW, MCCS, and 249 
ELSA where the women were older at baseline (median ranging from 55-58 years). JMWHS only 250 
provided categorical age (≤55 or >55 years), and almost half (48%) of the women were more than 55 251 
years of age.  252 
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Table 2 presents the distribution of some key harmonized demographic and reproductive variables 253 
by studies at baseline. Of the seven categories of ethnicity, Caucasian (75.5%, Australian/New 254 
Zealander 12.6%, European 61.7%, North American 1.2%) were the most prevalent, followed by 255 
Japanese (22.4%, mainly living in Japan (98.9%) but also some living in the USA). The remaining 256 
minority racial/ethnic groups included Hispanic/Latin American, Chinese, Middle Eastern, 257 
African/Blacks, and Others, with a minimum of 300 participants in each group. Within studies, four 258 
(SWAN, SMWHS, HILO, and SFMWHS) had a combination of multi-racial/ethnic samples. The 259 
level of education varied greatly between studies. Some variations were due to original study designs 260 
(e.g. study of nurses). However, this could also be reflecting regional variation in education. For 261 
example, DAMES-Morocco had a very small percentage of women (4%) with >12 years of education, 262 
while most US studies had over 75% at that level. Meanwhile, >12 years of education was 263 
significantly lower in NSHD compared with other UK studies. In most studies, the percentage of 264 
unmarried women was less than 10%, except for WHITEHALL and JNHS, which both had more 265 
than 20% single women. In WLH, more than double the average percentage of women (38.4%) were 266 
single because marital status was recorded from mother’s birth registry, so for those who had not 267 
given birth this information was missing. The overall prevalence of obesity (BMI ≥30 kg/m2) was 268 
10%. In four studies (ELSA, SWAN, SFMWHS, and DAMES-USA) nearly 30% of women were 269 
obese, while the corresponding figure for Japanese studies (JMWHS and JNHS) was less than 2%.  270 
Regarding reproductive factors, 40-60% of women reported that they had their first period (menarche) 271 
between the ages of 12 to 13 years. The percentage of women with earlier menarche (≤11 years) was 272 
around 20%, except for DNC and DAMES-Morocco where this was less than 10%. At baseline most 273 
women (57%) were still pre- or peri-menopausal, 20% reported natural menopause (range 0.8-55.6% 274 
among studies), 13% had hysterectomy or oophorectomy (range 1.7-29.6%), and the remaining 10% 275 
were taking either MHT or OCP. The distribution of vasomotor symptoms also varied considerably 276 
among studies, reflecting the range of age and menopausal status among studies. The studies with the 277 
oldest baseline age of late 50s (HOW, MCCS, ELSA, and JMWHS) had the highest proportions of 278 
naturally menopausal women (range 43.5-55.6%) and high prevalence of vasomotor symptoms (30-279 
50%). Conversely, studies with a younger baseline age of early 40s (WLH, SMWHS, and SFMWHS) 280 
had lower proportions of natural menopause (<3%) and lower prevalence of vasomotor symptoms 281 
(10-20%).      282 
The prevalence of CVD and diabetes at baseline for cross-sectional studies and at the end of the 283 
follow-up period for the 12 longitudinal studies are provided in Table 3. Overall, the median age at 284 
last follow-up for disease outcome was 56 years (IQR: 48-64 years). The prevalence of CVD and 285 
diabetes were higher in longitudinal studies that followed participants into their 60s or 70s of age. 286 
The overall prevalence of CVD was 7.2%, but it ranged from 0.9-24.6% between studies with the 287 
lowest in JNHS (median age 41 years) and the highest in ELSA (median age 65 years). Of the total 288 
CVD cases, 2.0% were stroke and 5.8% were heart disease. There was little variation in the prevalence 289 
of stroke between studies, except for ELSA, which had more than double the prevalence (5.6%) of 290 
other studies. A wider variation was evident in the prevalence of heart disease across studies, which 291 
ranged from 0.6-22.4%. The overall prevalence of diabetes was 5.1%, with JNHS having the lowest 292 
(1.3%) prevalence and SWAN the highest (13.2%). 293 
  294 
4. Discussion  295 
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With the pooled information from 230,000 mid-aged women across 20 cohort and cross-sectional 296 
studies, from ten countries, InterLACE has sufficient scale and heterogeneity to study the health of 297 
women in midlife. It provides a unique opportunity for advancing understanding of the relationships 298 
between reproductive characteristics and chronic diseases that are shown to have marked sex 299 
differences in their aetiology and prevalence. The study has assembled a broad spectrum of 300 
prospective data on mid-aged women, including socioeconomic status (education and marital status), 301 
lifestyle (BMI, smoking, and physical activities), reproductive factors (menarche, parity, and 302 
menopause), and disease outcomes (diabetes and CVD). It comprises a diverse range of race/ethnic 303 
groups (Caucasian, Asian, and Blacks) that enables inferences to be drawn regarding minority 304 
subgroups that would otherwise be underpowered in individual studies. This heterogeneity is 305 
important for detecting relationships that may not be apparent in homogeneous populations and 306 
increases the generalizability of the study findings.  307 
The overall distribution of measures in InterLACE data are broadly consistent with that in the 308 
published literature, for example, most of the women had their first menstrual period between 12 and 309 
13 years of age [43,44]. Similarly, the overall prevalence of obesity (10% at baseline) and diabetes 310 
(5% by final survey) among mid-aged women was comparable with the global prevalence of these 311 
conditions in the early 2000s [45,46].   312 
The process of combining individual-level data from multiple cohorts and cross-sectional studies for 313 
InterLACE inevitably leads to a number of methodological challenges. The contributing studies 314 
varied in their sampling methods, inclusion and exclusion criteria, and modes of survey 315 
administration. For instance, women may respond differently to questions about their reproductive 316 
health if the survey is completed on-line or via a telephone interview compared with a self-completed 317 
paper-based questionnaire, which was the most frequently used data collection method. Retention of 318 
participants is an issue for all longitudinal studies. The contributing studies have different levels of 319 
sample attrition and missing data due to withdrawal, mortality, and other reasons for non-response at 320 
each wave of data collection. The studies also varied greatly in terms of likely representativeness of 321 
the sample with respect to the relevant national population; for example sampling from specific 322 
professional groups as illustrated by women in the civil service for the Whitehall II study, or women 323 
nurses for the DNC and JNHS studies. Variations in the prevalence of CVD across studies already 324 
serve to illustrate the effect of differences in the age range of the cohorts of women when they 325 
responded to the relevant survey questions. Future analyses of the data from InterLACE will need to 326 
identify and adjust for these potential sources of heterogeneity and clustering of information. 327 
 328 
5. Conclusion 329 
Despite the challenges, this study profile shows that InterLACE has the potential to build a more 330 
detailed understanding of the differential effects of timing, frequency or duration of reproductive 331 
characteristics on the risk of key chronic disorders. This will allow for the development of distinct 332 
profiles of reproductive characteristics throughout life. Because these profiles are likely to be 333 
associated with risk of chronic disease in later life, they have the potential to be developed as the 334 
basis for a more tailored approach for preventive health strategies when women discuss reproductive 335 
issues with health professionals. Moreover, such health service encounters may present an 336 
opportunity for timely and targeted interventions to reduce chronic disease risk [47] that can be 337 
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enhanced to individual needs through understanding the interactions between reproductive health 338 
profiles and modifiable risk factors for cardiovascular and metabolic conditions. Crucially, 339 
InterLACE also enables a detailed review of methodologies currently used in the field of menopausal 340 
symptom research. This will result in recommendations for study design, symptom measures, and 341 
reporting of results to improve international and cross-cultural comparisons. Standardization of 342 
methods will become increasingly important to enhance the value of studies of women’s health in 343 
low and middle-income countries and where currently there are manifest gaps in knowledge. 344 
Further information is available on the InterLACE website http:/interlace.org.au. The pooled data set 345 
is governed by a Collaborative Research Agreement among several institutions. Those interested in 346 
collaborating on the project can contact the scientific committee at interlace@uq.edu.au. 347 
 348 
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Table 1 Twenty studies contributing to the InterLACE dataset (n=229,054) 
Study (abbreviation) Location 
Baseline  
survey year  
Baseline  
sample 
Baseline age 
median (IQR) 
No. of survey 
included 
Latest  
survey yearc 
Latest survey 
sample 
Longitudinal data provided (n=175,749)        
    Australian Longitudinal Study on Women’s Health (ALSWH) Australia 1996 13,715 48 (46-49) 7 2013  9,151 
    Healthy Ageing of Women Australia (HOW) Australia 2001 868 55 (52-57) 3 2011 325 
    Melbourne Collaborative Cohort Study (MCCS) Australia 1990-94 24,469 55 (48-62) 3 2003-2006 16,615 
    Danish Nurse Cohort Study (DNC) Denmark 1993/1999 28,731 50 (47-58) 2  1999 24,155 
    Women's Lifestyle and Health Study (WLH) Sweden/Norway 1991-92 49,259 40 (35-45) 2 2003-2004 34,402 
    MRC National Survey of Health and Development (NSHD)  UK 1993† 1,570 47a 8 2000 1,307 
    National Child Development Study (NCDS) UK 2008† 5,274 50a 2 2013 4,635 
    English Longitudinal Study of Ageing (ELSA) UK 2002-09 9,118 58 (52-68) 5 2010-2011 5,649 
    UK Women's Cohort Study (UKWCS) UK 1995-98 35,522 51 (45-59) 2 1999-2004 19,004 
    Whitehall II (WHITEHALL) UK 1985-88 3,413 45 (40-51) 8 2006 2,156 
    The Study of Women's Health Across the Nation (SWAN) USA 1996 3,302 46 (44-48) 11 2006 2,239 
    Seattle Midlife Women’s Health Study (SMWHS) USA 1990-92 508 41 (38-44) 2 2000 194 
Cross-sectional data provided (n=53,305)        
    Japan Nurses’ Health Study (JNHS) Japan 2001-2007 49,927 41 (35-47)    
    Japanese Midlife Women’s Health Study (JMWHS) Japan 2002 847 N/A (45-60)b    
    Hilo Women's Health Study (HILO) USA 2004-05 994 51 (46-56)    
    San Francisco Midlife Women’s Health Study (SFMWHS) USA 1996 347 43 (42-45)    
    The Decision at Menopause Study (DAMES-USA) USA 2001 293 50 (48-53)    
    The Decision at Menopause Study (DAMES-Lebanon) Lebanon 1997 298 50 (48-53)    
    The Decision at Menopause Study (DAMES-Spain) Spain 2002 300 50 (47-53)    
    The Decision at Menopause Study (DAMES-Morocco) Morocco 1998 299 49 (46-52)    
Abbreviation: N/A, not applicable; IQR, interquartile range.  
a NSHD (1946 British Birth Cohort) and NCDS (1958 British Birth Cohort) first collected information on women health in 1993 (aged 47) and in 2008 (aged 50), respectively, so we used 1993 and 2008 as the baseline year for the 
InterLACE.   
b JMWHS provided age by category only, and 48% of women were aged more than 55 (age range: 45-60 years). 
c The latest survey data contributed to the InterLACE dataset.   
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Table 2: Baseline demographic and reproductive variables for the 20 studies  
  Race/Ethnicity (%)  Educationa (%)  Marital status (%) 
Study  n Caucasian 
Hispanic/ 
Latino 
Asia-
Japanese 
Asia-
Chinese 
Middle 
Eastern 
African/ 
black Other n 
≤10  
years 
11-12 
years 
>12  
years n 
Married/ 
partnered 
Separated/ 
divorced/ 
widowed 
Never 
married/ 
single 
Overall 229,054 75.5 0.2 22.4 0.2 0.3 0.5 1.0 223,733 29.4 11.7 58.9 197,768 69.6 14.6 15.8 
Longitudinal data                 
    ALSWH 13,715 96.1 0.3 0.1 0.4 0.2 N/A 2.8 13,577 50.1 16.8 33.1 13,647 82.9 13.9 3.3 
    HOW 868 96.5 N/A N/A N/A N/A N/A 3.5 859 52.4 15.9 31.7 861 76.4 19.3 4.3 
    MCCS 24,469 100 N/A N/A N/A N/A N/A N/A 24,465 63.0 9.2 27.8 23,391 69.3 22.2 8.5 
    DNC 28,731 100 N/A N/A N/A N/A N/A N/A 28,731 0.0 0.0 100 28,484 69.8 20.0 10.2 
    WLH 49,259 100 N/A N/A N/A N/A N/A N/A 48,755 29.7 28.4 41.9 23,727b 60.2 1.4 38.4 
    NSHD 1,570 100 N/A N/A N/A N/A N/A N/A 1,482 70.4 23.8 5.8 1,442 80.5 14.7 4.8 
    NCDS 5,274 98.0 N/A N/A N/A N/A 0.2 1.8 4,546 62.5 10.4 27.1 4,893 68.5 22.4 9.1 
    ELSA 9,118 96.4 N/A N/A N/A N/A 0.5 3.0 8,939 71.3 7.1  21.6 8979 65.3 29.4 5.4 
    UKWCS 35,522 98.7 N/A N/A 0.1 N/A 0.1 1.1 32,320 48.2 12.1 39.7 34,818 75.0 17.4 7.6 
    WHITEHALL 3,413 84.2 N/A N/A N/A N/A N/A 15.8 3008 55.3 16.3 28.5 3,395 61.2 17.2 21.6 
    SWAN 3,302 46.9 8.7 8.5 7.6 N/A 28.3 N/A 3,271 7.3 17.8 75.0 3,248 66.1 20.3 13.5 
    SMWHS 508 77.2 1.2 N/A N/A N/A 11.4 10.2 507 0.6 14.6 84.8 507 68.4 24.7 6.9 
Cross-sectional data                 
    JNHS 49,927 N/A N/A 100 N/A N/A N/A N/A 49,927 0.0 0.8 99.2 48,843 67.9 7.9 24.2 
    JMWHS 847 N/A N/A 100 N/A N/A N/A N/A 826 9.9 58.6 31.5 N/A N/A N/A N/A 
    HILO 994 24.2 0.9 29.7 0.9 N/A 0.1 44.2 990 1.8 14.3 83.8 N/A N/A N/A N/A 
    SFMWHS 347 46.4 27.4 N/A N/A N/A 26.2 N/A 342 4.1 6.4 89.5 343 57.4 28.6 14.0 
    DAMES-USA 293 94.2 1.0 N/A N/A N/A 2.0 2.7 293 2.4 28.7 68.9 293 73.0 18.1 8.9 
    DAMES-Lebanon 298 N/A N/A N/A N/A 100 N/A N/A 296 75.0 11.0 15.0 298 87.2 12.8 0.0 
    DAMES-Spain 300 95.3 3.7 N/A N/A 0.3 N/A 0.7 300 46.3 19.0 34.7 300 70.3 10.3 19.3 
    DAMES-Morocco 299 N/A N/A N/A N/A 100 N/A N/A 299 87.3 8.7 4.0 299 78.3 19.1 2.7 
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(Continue) 
  Body mass index (%)  Age at menarche (%)  Menopausal status (%)  Vasomotor symptomsh (%) 
Study  n 
Normal 
<25  
kg/m2 
Overweight  
25-29.9 
kg/m2 
Obese  
≥30 
kg/m2 n 
≤11 
years 
12-13 
years 
 ≥14 
years n 
Hade 
surgery 
Current 
MHT 
use 
Current 
OCP 
use 
Pre-/peri-
menopause 
Natural 
menopause n 
Hot 
flashes n 
Night 
sweats 
Overall 219,351 66.9 23.2 10.0 214,759 16.9 49.8 33.2 223,775 12.6 6.5 3.8 57.2 20.0 30,309 46.1 27,085 38.3 
Longitudinal data                   
    ALSWH 13,179 52.5 28.9 18.6 11,396 18.8 49.4 31.8 13,674 23.5 9.2 5.5 56.3 5.5 13,624 49.6 13,614 39.4 
    HOW 821 43.2 32.0 24.7 508d 19.5 43.3 37.2 861 29.6 7.7 N/A 14.5 48.2 851 44.8 846 38.2 
    MCCS 24,454 41.9 36.2 21.9 24,389 16.5 45.7 37.8 24,030 20.3 4.8 1.6 29.7 43.5 N/A N/A N/A N/A 
    DNC 28,533 71.5 22.8 5.6 28,477 7.9 43.0 49.1 28,675 13.1 12.8 2.2 37.7 34.2 N/A N/A N/A N/A 
    WLH 47,234 72.4 21.8 5.8 48,544 12.9 54.4 32.6 48,897 6.9 4.0 12.2 74.3 2.5 N/A N/A N/A N/A 
    NSHD 1,429 60.7 25.5 13.8 1,242 16.2 64.2 19.6 1,492 14.9 11.3 2.9 65.0 5.8 1535 37.2 1532 30.9 
    NCDS 4,158 44.4 33.0 22.6 4,227 16.5 57.7 25.7 4,896 17.2 6.8 6.4 48.2 21.3 4,894 64.3 4,895 51.9 
    ELSA 7,485 34.4 37.6 28.0 6,314d 20.9 39.5 39.6 7,049 19.5 11.0 1.2 16.4 51.9 N/A N/A N/A N/A 
    UKWCS 33,990 64.8 25.4 9.8 34,596 22.1 46.0 31.8 3,4909 19.4 13.6 N/A 39.2 27.8 N/A N/A N/A N/A 
    WHITEHALL 3,411 61.1 27.9 11.0 N/A N/A N/A N/A 3,268 12.2 1.7 6.2 58.9 21.0 2,704 35.3 N/A N/A 
    SWAN 3,260 40.1 26.9 33.0 3,267 24.2 52.7 23.1 3,225 N/A N/A N/A 100f N/A 3,285 26.7 3,284 29.3 
    SMWHS 507 55.4 25.8 18.7 507 22.9 57.8 19.3 506 N/Af 5.9 3.0 90.3 0.8 361 10.5 361 8.0 
Cross-sectional data                   
    JNHS 47,831 87.2 11.0 1.8 49,175 21.0 54.1 25.0 48,968 5.7 0.2 N/A 82.5 11.6 N/A N/A N/A N/A 
    JMWHS 825 85.7 13.1 1.2 N/A N/A N/A N/A 813 11.3 2.1 N/A 31.0 55.6 830 46.5 827 25.5 
    HILO 955 46.9 29.7 23.4 972 25.4 52.8 21.8 982 21.5 5.6 3.5 38.7 30.8 994 32.1 994 25.2 
    SFMWHS 96 36.5 32.3 31.3 N/A N/A N/A N/A 343 1.7 N/A N/A 97.1 1.2 339 17.1 339 21.8 
    DAMES-USA 293 43.7 29.0 27.3 291 22.3 49.1 28.5 293 16.0 N/A N/A 50.0 34.0g 293 56.7 292 35.6 
    DAMES-Lebanon N/Ac N/A N/A N/A 298 21.1 42.3 36.6 297 11.0 N/A  N/A  55.0 34.0g 271 48.0 N/A N/A 
    DAMES-Spain 300 59.0 33.0 8.0 297 20.9 54.9 24.2 300 9.0 N/A N/A 53.0 38.0g 300 45.7 300 34.0 
    DAMES-Morocco N/Ac N/A N/A N/A 259 10.0 45.6 44.4 297 2.0 N/A N/A 55.0 43.0g 299 61.2 N/A N/A 
Abbreviation: N/A, not applicable; MHT, menopause hormone therapy; OCP, oral contraceptive pill.   
a Education ≤10 years corresponds to less than high school (equivalent to CSE or GCE O level in the UK), 11-12 years to high school (equivalent to GCE A level in the UK), and >12 years to at least some college (including trade, 
certificate, vocational training, diploma, and university degree).  
b In the WLH study, marital status was only recorded from mothers’ birth registry hence the data were missing for all women who did not give birth. 
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c Body mass index data were reported as body weight appearance by category only (e.g. normal, overweight, obese), instead of measured or self-reported weight and height.  
d In the HOW study, age at menarche was only collected from survey 2 in 2006; in the ELSA study, age at menarche was only collected at wave 3 and wave 4 hence the data were missing for those women who lost to follow-up.  
e Had surgery category included hysterectomy or oophorectomy. 
f The baseline eligibility criteria for the SWAN study were: at least one menstrual period in the previous three months, without surgical removal of the uterus and/or both ovaries, and without the current use of hormone therapy. The 
baseline eligibility for the SMWHS study was without surgical removal of uterus or ovaries.      
g In the DAMES studies, women on MHT use were categorised as post-menopause.  
h Vasomotor symptoms were asked whether participants had experienced the symptoms in different time periods prior to baseline: in the last 12 months (ALSWH, NSHD, and NCDS), in the past month (DAMES studies), in the last 
one/two weeks (SFMWHS, SWAN, and HILO), and in the past 24 hours/at the moment (HOW, WHITEHALL, SMWHS, and JMWHS).     
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Table 3 The prevalence of chronic diseases at the end of study follow-up for the 20 studies  
  Cardiovascular disease  Diabetes 
Study 
Age at last follow-up 
median (IQR) n 
Stroke and/or 
heart disease  
(%) n 
Stroke 
(%) n 
Heart  
diseasesc 
(%) 
 
 n 
Type 1 or  
Type 2 
 (%) 
Overall  56 (48-64) 218,082 7.2 217,608 2.0 217,992 5.8  223,211 5.1 
Longitudinal dataa           
    ALSWH 63 (60-65) 13,714 12.3 13,714 2.9 13,713 10.7  13,714 12.0 
    HOW 63 (60-66) 522 13.2 515 2.3 521 11.5  523 11.1 
    MCCS 64 (57-71) 24,467 10.3 24,467 2.9 24,467 8.3  24,467 7.3 
    DNC 64 (50-73)b 28,640 10.9 28,592 2.9 28,632 8.5  28,554 4.8 
    WLH 59 (54-64)b 49,149 6.0 49,021 2.2 49,148 4.2  49,258 6.1 
    NSHD 64b 1,526 13.6                     1,518 0.8 1,503 13.2  1,526 6.0 
    NCDS 55 N/A N/A N/A N/A N/A N/A  5,274 5.7 
    ELSA 65 (58-75) 9,118 24.6 9,115 5.6 9,118 22.4  9,115 9.4 
    UKWCS 53 (47-62) 33,607 4.5 33,334 1.1 33,558 3.6  33,372 2.4 
    WHITEHALL 61 (56-67) 3,413 18.0 3,413 2.2 3,413 16.6  3,413 10.2 
    SWAN 54 (52-57) 3,302 7.8 3,300 3.1 3,296 5.5  3,296 13.2 
    SMWHS 48 (42-55)b N/A N/A N/A N/A N/A N/A  508 4.1 
Cross-sectional dataa           
    JNHS 41 (35-47) 49,658 0.9 49,658 0.3 49,658 0.6  49,658 1.3 
    JMWHS N/A (45-60) N/A N/A N/A N/A N/A N/A  N/A N/A 
    HILO 51 (46-56) 966 6.2 961 2.2 965 4.8  N/A N/A 
    SFMWHS 43 (42-45) N/A N/A N/A N/A N/A N/A  234 2.1 
    DAMES-USA 50 (48-53) N/A N/A N/A N/A N/A N/A  N/A N/A 
    DAMES-Lebanon 50 (48-53) N/A N/A N/A N/A N/A N/A  N/A N/A 
    DAMES-Spain 50 (47-53) N/A N/A N/A N/A N/A N/A  N/A N/A 
    DAMES-Morocco 49 (46-52) N/A N/A N/A N/A N/A N/A  299 5.4 
N/A, not applicable; IQR, interquartile range. 
a Longitudinal studies provided the cumulative prevalence of chronic diseases over the study follow-up period. Once women reported they had CVD or diabetes, their disease status carried forward at subsequent surveys. Cross-sectional 
studies only provided the prevalence of disease at baseline.  
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b DNC, WLH, and SMWHS provided diseases outcome data from survey questionnaires and also from hospital registries (DNC: 1993-2013, WLH: 1991-2010, SMWHS: 1990-2013). NSHD also provided disease outcome data from the 
latest 2010 survey, when cohort members were aged 64 years.       
c Heart diseases included general heart disease, heart attack, heart failure and angina.  
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Figure legends 
Figure 1 Locations of the 20 studies contributing to the InterLACE study 
There are ten participating countries: Australia, Demark, Sweden, Norway, UK, USA, Japan, 
Lebanon, Spain, and Morocco.  
 
Figure 2 Example of data harmonization to obtain common categories for race/ethnicity    
 
Figure 3 Example of data harmonization to obtain common categories for menopausal status. 
Abbreviations: MHT, menopause hormone therapy; OCP, oral contraceptive pill.  
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There are ten participating countries: Australia, Demark, Sweden, Norway, UK, USA, Japan, 
Lebanon, Spain, and Morocco.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 25 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
                                                      
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2 Example of data harmonization to obtain common categories for race/ethnicity    
 
 
insufficient 
information  
10 studies had self-reported race/ethnicity  
(MCCS, NCDS, ELSA, UKWCS, WHITEHALL, 
SWAN, SMWHS, HILO, SFMWHS, DAMES-USA) 
10 studies did not have race/ethnicity variable   
 Race/ethnicity  
Race/Ethnicity 10 categories 
 
1. Caucasian-Australian/New Zealander 
2. Caucasian-European  
3. Caucasian-North American 
4. Hispanic/Latin American  
5. Asian-Japanese  
6. Asian-Chinese  
7. Asian-Other (South/Southeast Asian) 
8. Middle Eastern 
9. African/Black  
10. Other (Native American, Pacific 
Islander, Caribbean, Hawaiian, mixed) 
Race/Ethnicity 7 categories 
 
1. Caucasian (Australian/New Zealander, 
European, North American) 
2. Hispanic/Latin American  
3. Asian-Japanese  
4. Asian-Chinese  
5. Middle Eastern 
6. African/Black 
7. Other (Asian-Other, Native American, 
Pacific Islander, Caribbean, Hawaiian,  
mixed)  
 
5 studies had data on related variables 
1. Country of birth* (ALSWH, HOW, 
NSHD, DAMES-Spain) or country 
of residency in childhood (WLH)  
2. Language spoken at home (ALSWH, 
HOW) 
*Note:  
a. Women who born in South Africa and 
had migrated to Australia or Spain were 
categorised as Caucasian. 
b. Women born in South America and 
Central America countries were 
categorised as Hispanic/Latin American. 
c. Morocco and Egypt were categorised 
as Middle Eastern countries.   
d. Women born in China, Hong Kong, 
and Taiwan were categorised as Chinese, 
while women born in Singapore/Malaysia 
were categorised as Asian-other.   
  
5 studies only had data on 
country of study 
Country of residency 
(DNC, JNHS, JMWHS, 
DAMES-Lebanon, 
DAMES-Morocco) 
 
insufficient 
information  
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Figure 3 Example of data harmonization to obtain common categories for menopausal status 
Abbreviations: MHT, menopause hormone therapy; OCP, oral contraceptive pill  
if insufficient information 
14 studies had menopausal status derived or 
reasons why period stopped  
(ALSWH, HOW, WLH, NSHD, NCDS, SWAN, SMWHS, 
JNHS, JMWHS, SFMWHS, DAMES-USA, DAMES-Spain, 
DAMES-Lebanon, DAMES-Morocco) 
6 studies did not have menopausal status derived 
or reasons why period stopped variable  
(MCCS, DNC, ELSA, UKWCS, WHITEHALL, HILO) 
 
 
 Menopausal status  
 
Menopausal status 6 categories  
 
1. Hysterectomy/Oophorectomy 
2. Current MHT use 
3. Current OCP use 
4. Pre-menopause  
5. Peri-menopause 
6. Natural menopause 
Menopausal status 5 categories  
 
1. Hysterectomy/Oophorectomy 
2. Current MHT use 
3. Current OCP use 
4. Pre-/Peri-menopause 
5. Natural menopause 
 
Use relevant variables and follow the rules below 
to define menopausal status 
If hysterectomy=yes or oophorectomy=yes           
then menopausal status=1; 
else if current MHT use=yes                                   
then menopausal status=2; 
else if current OCP use=yes                                          
then menopausal status=3;  
else if period in the last 12 month=no                   
then menopausal status=6; 
else if period in the last 12 month=yes and (period 
changed/unpredictable/irregular=yes or                        
period in the last 3 month=no)                                                         
then menopausal status=5;                                                                             
else if  period in the last 12 month=yes                            
then menopausal status=4;           
*For the longitudinal studies, once women have 
gone through natural menopause or surgery the 
status must carry forward at subsequent surveys.                                 
 
  
